Nazol Baby, nasal drops, 10 ml

Release form, composition and packaging

Nasal drops 0.125% in the form of a clear solution, from colorless to light yellow, odorless.

100 ml

phenylephrine hydrochloride 0.125 g

benzalkonium chloride - 0.018 g, glycerol - 5 g, macrogol 1500 - 1.5 g, sodium hydrogen phosphate dihydrate - 0.226 g, potassium dihydrogen phosphate - 0.101 g, disodium edetate dihydrate - 0.02 g, purified water - 94.76 g.

5 ml - polyethylene bottles (1) - cardboard packs.

10 ml - polyethylene bottles (1) - cardboard packs.

15 ml - polyethylene bottles (1) - cardboard packs.

30 ml - polyethylene bottles (1) - cardboard packs.

pharmachologic effect

A vasoconstrictor drug for topical use in ENT practice, is an agonist of α 1-adrenergic receptors (sympathomimetic).

It has a vasoconstrictor effect by stimulating β 1-adrenergic receptors in the nasal mucosa: reduces swelling, congestion and hyperemia of tissues in the nasal mucosa, and also improves the patency of the nasal airways.

Pharmacokinetics

With local application of the drug, systemic absorption is low.

Indications for use

To facilitate breathing through the nose when:

- colds and flu

- hay fever or other allergic diseases of the upper respiratory tract, accompanied by acute rhinitis or sinusitis.

Contraindications for use

- diseases of the cardiovascular system (including coronary sclerosis, angina pectoris)

- hypertensive crisis

- thyrotoxicosis

- diabetes

- hypersensitivity to drug components.

The drug is used with caution in children under 6 years of age.

Dosage regimen

The drug is administered intranasally.

The duration of treatment is no more than 3 days.

For children under the age of 1 year, a single dose - 1 drop no more often than every 6 hours.

For children aged 1 to 6 years, a single dose is 1-2 drops.

For children over the age of 6 and adults, a single dose is 3-4 drops.

For instillation, you must slightly squeeze the bottle, holding it upside down.

After use, wipe the pipette dry on the bottle.

Overdose

There are no data on drug overdose.

Symptoms: possible with systemic absorption - ventricular extrasystole, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, excessive increase in blood pressure, agitation.

Treatment: intravenous administration of short-acting alpha-blockers (phentolamine) and beta-blockers (for rhythm disturbances).

Side effect

From the side of the central nervous system: headache, dizziness, tremor, sleep disturbance.

From the side of the cardiovascular system: palpitations, arrhythmias, increased blood pressure.

Local reactions: sometimes - burning, tingling or tingling in the nose.

Others: sweating, pallor.

Drug interactions

MAO inhibitors (procarbazine, selegiline), tricyclic antidepressants, maprotiline, guanedrel, guanethidine increase the pressor effect and arrhythmogenicity of phenylephrine (with systemic absorption).

Thyroid hormones increase (mutually with systemic absorption of phenylephrine) the associated risk of coronary insufficiency (especially in coronary atherosclerosis).

Application during pregnancy and lactation

There is no sufficient experience in using the drug during pregnancy.

The use of the drug during pregnancy and lactation (breastfeeding) is possible only if the intended benefit to the mother outweighs the potential risk to the fetus or child.

Special instructions In children under the age of 1 year, the drug should be used strictly according to the doctor's prescription and no more often than every 6 hours. In children, systemic absorption of phenylephrine and the associated risk of side effects is higher than in adults.

Phenylephrine should not be prescribed to patients within 2 weeks after discontinuation of MAO inhibitors, as they could

Name ENG

NAZOL BABY

Clinical and pharmacological group

A vasoconstrictor drug for local use in ENT practice

ATX code

Phenylephrine

Dosage

0.125% x 10ml

Structure

1 fl.

contains: active substance: phenylephrine hydrochloride 0.125 g

Indications

symptomatic treatment of acute rhinitis or sinusitis with colds, flu, allergic diseases of the upper respiratory tract.

INN / Active ingredient

phenylephrine hydrochloride

Contraindications

increased individual sensitivity to the ingredients of Nazol Baby diseases of the cardiovascular system (including coronary sclerosis, angina pectoris) hypertensive crisis thyrotoxicosis diabetes mellitus. With caution: children under 6 years of age pregnancy lactation.

Storage conditions and periods

At a temperature not higher than 30 degrees.

Expiration date: 2 years

Specifications

Category

Runny nose

Scope of the medicinal product

Ear, Throat, Nose

Release form

Drops

Manufacturer country

Italy

Package quantity, pcs

one

Minimum age from

No restrictions

Way of introduction

Through the respiratory tract

Vacation conditions

Without recipe

Volume, ml.

10 ml

Brand name

Bayer

The amount of the dosage form in the primary package

10 ml

Primary packaging type

Bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Decongestant - alpha adrenergic agonist

Anatomical and therapeutic characteristics

R01AA04 Phenylephrine

Dosage form

Nasal drops

Dosage (volume) of the substance in the preparation

phenylephrine hydrochloride 0.125 g

Expiration date in days

730

The target audience

Children

Package weight, g

45

Mode of application

:

Nazol Baby is used intranasally, squeeze the bottle slightly, holding it upside down.

For children under the age of 1 year: a single dose - 1 drop no more often than every 6 hours For children aged 1 to 6 years: a single dose - 1-2 drops For children over the age of 6 and adults: single dose - 3-4 drops. After use, wipe dry the pipette on the bottle. The duration of treatment is no more than 3 days.

Information on technical characteristics, delivery set, country of manufacture